SIGLEC12 expression was found to be upregulated in bladder urothelial carcinoma (BLCA), cervical squamous cell carcinoma (CESC), esophageal earcinoma (ESCA), and Glioblastoma multiforme tumours (GBM) when compared to the normal sample type (Fig. 2). Here, SIGLEC12 is linked to cervical squamous cell carcinoma.